DaVita Inc. Announces Receipt of DOJ Subpoena in Connection with Previously Reported Investigation

EL SEGUNDO, Calif., Dec. 15 DaVita Inc.(NYSE: DVA), today announced that it is working with the U.S. Department ofHealth and Human Services, Office of Inspector General ("OIG") to respond to asubpoena request for documents issued in connection with the civilinvestigation by the Department of Justice and the U.S. Attorney's Office forthe Northern District of Georgia previously reported in the Company'sQuarterly Report on 10-Q for the period ended September 30, 2008. Thesubpoena was sent from the OIG's office in Atlanta, Georgia and was receivedby the Company on December 12, 2008. The subpoena applies to the Company andits subsidiaries and covers a time period from January 1, 2003 to the present.In response to the subpoena, DaVita will produce a wide range of documentsrelating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlicit,and Epogen. The Company intends to meet with representatives of thegovernment to discuss the scope of the subpoena and the production ofresponsive documents.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO)

To the Company's knowledge, no proceedings have been initiated against theCompany at this time, although the Company cannot predict whether or whenproceedings might be initiated. The Company intends to cooperate with thegovernment's investigation.

"DaVita has been involved in several investigations over the last 9 years,including some covering issues that are repeated in this subpoena. We respectthe government's need to ensure the appropriateness of healthcare providerpractices, especially during times when pharmaceutical issues involvesignificant expense for Medicare. We look forward to meeting with governmentrepresentatives on this new investigation and once again demonstrating thestrength of our clinical outcomes and the integrity and comprehensiveness ofDaVita's Compliance programs," said LeAnne Zumwalt, spokesperson for DaVita.

DaVita is a leading provider of kidney care in the United States,providing dialysis services and education for patients with chronic kidneyfailure and end stage renal disease. DaVita manages more than 1,400 outpatientfacilities and acute units in more than 700 hospitals located in 43 states andthe District of Columbia, serving approximately 110,000 patients.

SOURCE DaVita Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...